How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daclizumab-or-basiliximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Daclizumab or Basiliximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daclizumab or Basiliximab (Daclizumab or Basiliximab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-2 receptor antagonist (monoclonal antibody). Area: Immunology.

phase 3 IL-2 receptor antagonist (monoclonal antibody) CD25 (IL-2 receptor alpha subunit) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Daclizumab or Basiliximab (Daclizumab or Basiliximab) — National Institute of Allergy and Infectious Diseases (NIAID). Daclizumab and Basiliximab are monoclonal antibodies that block the IL-2 receptor (CD25) on T cells, preventing T cell activation and proliferation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Daclizumab or Basiliximab TARGET	Daclizumab or Basiliximab	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	IL-2 receptor antagonist (monoclonal antibody)	CD25 (IL-2 receptor alpha subunit)
Basiliximab (Simulect)	Basiliximab (Simulect)	Novartis	phase 3	IL-2 receptor antagonist (monoclonal antibody)	CD25 (IL-2 receptor alpha chain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-2 receptor antagonist (monoclonal antibody) class)

National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daclizumab or Basiliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/daclizumab-or-basiliximab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab